BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

NCT00095459 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

NIH

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Bevacizumab
DRUG: BAY 43-9006

Sponsor

National Cancer Institute (NCI)